A pilot study evaluating the use of sirolimus in children and young adults with desmoid‐type fibromatosis
Aaron R. Weiss, Sarah Dry, Clara Maygar, Anya Cutler, Christine W. Lary, Carmen Khoo, Jillian E. Fergione, Melanie M. Hounchell, Kathleen Glick, Meghen B. Browning, Sun Choo, Douglas S. Hawkins, Joanne Lagmay, Michelle Manalang, Stephen X. Skapek, Brenda J. Weigel, Stephanie L. Verwys, Noah Federman
Abstract
Deregulation of the mTOR pathway may play an important role in tumor biology when the APC/β-catenin pathway is disrupted in desmoid-type fibromatosis (DT). A pilot study was conducted to determine whether sirolimus can block the mTOR pathway (primary aim) as well as determine whether it can safely be given in the preoperative setting, decrease tumor size/recurrence, and decrease tumor-associated pain in children and young adults (secondary aims) with DT. Nine subjects ages 5-28 years were enrolled from 2014 to 2017 across four centers. Sirolimus was feasible and was associated with a nonstatistically significant decrease in pS706K activation.